Different approval pathways can be explored while entering the European pharmaceutical market. The approval pathways include:

• Centralized Procedure (CP)
• Decentralized Procedure (DCP)
• National Procedure (NP)
• Mutual Recognition Procedure (MRP)

Our experts discuss the most explored pathways, CP and DCP, and the eligibility criteria to pursue them for product approval and marketing authorization within the European Union (EU). 

Reference Links

• EMA overview of the centralised authorisation procedure
• European Commission summary of national authorization procedures
• CMDh guidance on marketing authorization applications